PL3474904T3 - Otrzymywanie przeciwciał monoklonalnych znakowanych 212pb - Google Patents

Otrzymywanie przeciwciał monoklonalnych znakowanych 212pb

Info

Publication number
PL3474904T3
PL3474904T3 PL17732126.2T PL17732126T PL3474904T3 PL 3474904 T3 PL3474904 T3 PL 3474904T3 PL 17732126 T PL17732126 T PL 17732126T PL 3474904 T3 PL3474904 T3 PL 3474904T3
Authority
PL
Poland
Prior art keywords
obtaining
monoclonal antibodies
labelled monoclonal
labelled
antibodies
Prior art date
Application number
PL17732126.2T
Other languages
English (en)
Inventor
Roy Hartvig Larsen
Original Assignee
Sciencons AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sciencons AS filed Critical Sciencons AS
Publication of PL3474904T3 publication Critical patent/PL3474904T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1051Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/008Peptides; Proteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL17732126.2T 2016-06-24 2017-06-23 Otrzymywanie przeciwciał monoklonalnych znakowanych 212pb PL3474904T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16176263 2016-06-24
PCT/EP2017/065508 WO2017220767A1 (en) 2016-06-24 2017-06-23 Preparation of 212pb labeled monoclonal antibodies

Publications (1)

Publication Number Publication Date
PL3474904T3 true PL3474904T3 (pl) 2024-12-16

Family

ID=56263569

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17732126.2T PL3474904T3 (pl) 2016-06-24 2017-06-23 Otrzymywanie przeciwciał monoklonalnych znakowanych 212pb

Country Status (11)

Country Link
US (1) US11306038B2 (pl)
EP (1) EP3474904B1 (pl)
JP (1) JP7176958B2 (pl)
CN (1) CN109310789B (pl)
AU (1) AU2017281649B2 (pl)
CA (1) CA3026599A1 (pl)
ES (1) ES2991349T3 (pl)
IL (1) IL263808B2 (pl)
MX (1) MX2018016121A (pl)
PL (1) PL3474904T3 (pl)
WO (1) WO2017220767A1 (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US9725710B2 (en) 2014-01-08 2017-08-08 Flodesign Sonics, Inc. Acoustophoresis device with dual acoustophoretic chamber
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
JP2021507561A (ja) 2017-12-14 2021-02-22 フロデザイン ソニックス, インク.Flodesign Sonics, Inc. 音響トランスデューサドライバ及びコントローラ
MX2022006638A (es) 2019-12-05 2022-07-19 Sciencons AS Producción de 212pb altamente purificados.
IL310474A (en) 2021-08-11 2024-03-01 Nuclear Res And Consultancy Group System and method of production and isolation of charged radionuclides
JP2025507661A (ja) * 2022-02-24 2025-03-21 アルファ タウ メディカル リミテッド 対流強化拡散アルファエミッタ放射線療法
JP7816003B2 (ja) * 2022-06-06 2026-02-18 Jfeエンジニアリング株式会社 放射性物質の標識方法
US20240091705A1 (en) * 2022-09-16 2024-03-21 Viewpoint Molecular Targeting, Inc. Removal of free-unlabeled cationic and anionic solution phase radionuclides from radiopharmaceuticals using solid-phase extraction techniques
US20250332297A1 (en) 2024-01-31 2025-10-30 Molecular Partners Ag Dll3-specific binding constructs and their use in radiotherapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO312708B1 (no) * 2000-02-21 2002-06-24 Anticancer Therapeutic Inv Sa Radioaktive liposomer til terapi
DE10040771A1 (de) 2000-08-21 2002-03-14 Altmann Therapie Gmbh & Co Kg Neue, 224Ra enthaltende, radiotherapeutisch wirksame Formulierungen und Verfahren zu ihrer Herstellung
DE10347459B3 (de) * 2003-10-13 2005-05-25 Actinium Pharmaceuticals, Inc. Radium-Target sowie Verfahren zu seiner Herstellung
SI1853718T1 (sl) * 2005-02-15 2016-02-29 Duke University Protitelesa anti-CD19 in uporabe v onkologiji
WO2012032043A1 (en) * 2010-09-07 2012-03-15 Areva Med Llc 212 pb imaging
ES2657388T3 (es) * 2015-02-26 2018-03-05 Sciencons AS Disoluciones radiofarmacéuticas con propiedades ventajosas
US9433690B1 (en) * 2015-02-26 2016-09-06 Sciencons AS Radiopharmaceutical solutions with advantageous properties
DK3261681T3 (da) 2015-02-26 2020-04-27 Sciencons AS Radiofarmaceutiske opløsninger med fordelagtige egenskaber

Also Published As

Publication number Publication date
IL263808A (en) 2019-02-03
EP3474904B1 (en) 2024-08-07
WO2017220767A1 (en) 2017-12-28
CN109310789A (zh) 2019-02-05
EP3474904A1 (en) 2019-05-01
AU2017281649B2 (en) 2023-07-27
IL263808B2 (en) 2025-04-01
US20190194087A1 (en) 2019-06-27
JP7176958B2 (ja) 2022-11-22
CN109310789B (zh) 2021-12-03
US11306038B2 (en) 2022-04-19
AU2017281649A1 (en) 2019-01-03
IL263808B1 (en) 2024-12-01
ES2991349T3 (es) 2024-12-03
JP2019523232A (ja) 2019-08-22
NZ749058A (en) 2025-07-25
CA3026599A1 (en) 2017-12-28
MX2018016121A (es) 2019-05-30

Similar Documents

Publication Publication Date Title
IL272227A (en) Anti-tigit antibodies
IL269405A (en) Anti-sirp alpha antibodies
IL272274A (en) B7-h4 antibodies and methods of use thereof
DK3625259T3 (da) Anti-sirpalpha-antistoffer
EP3661558A4 (en) ANTI-IL1RAP ANTIBODIES
PT3606954T (pt) Anticorpos anti-lag3
EP3569709A4 (en) ANTI-GPC3 ANTIBODIES
EP3532489A4 (en) ANTI-TL1A NEUTRALIZING MONOCLONAL ANTIBODIES
DK3455257T3 (da) Anti-pd-l1-antistoffer
EP3387442A4 (en) HUMANIZED ANTI-CD73 ANTIBODIES
HUE051700T2 (hu) Anti-PD-1 antitestek
EP3481869A4 (en) ANTI-CD73 ANTIBODIES
EP3691447A4 (en) ANTI-TRANSTHYRETINE ANTIBODY
DK3332006T3 (da) Hidtil ukendte anti-PD-L1-antistoffer
PL3474904T3 (pl) Otrzymywanie przeciwciał monoklonalnych znakowanych 212pb
DK3441086T3 (da) Monoklonalt anti-PD-1-antistof
KR20180085002A (ko) 인간화된 항-cll-1 항체
DK3606961T3 (da) Garp-tgf-beta-antistoffer
DK3452513T3 (da) Humaniserede anti-il-ir3-antistoffer
IL256097A (en) Antibody epitope
DK3649152T3 (da) ROR1-antistoffer
HUE061076T2 (hu) Humanizált anti-C1s ellenanyagok alkalmazási eljárások
EP3487518A4 (en) HUMANIZED MONOCLONAL ANTIBODIES TARGETING VE-PTP (HPTP-SS)
EP3532034A4 (en) ANTI-APOE ANTIBODY
EP3567053A4 (en) ANTI-CLAUDINE-2 MONOCLONAL ANTIBODY